Stock Events

Stock Events

Diamyd Medical AB

SEK10.30

0

+SEK0.00+0% Tuesday 15:29

Statistics

Day High

10.3

Day Low

10.3

52W High

11.2

52W Low

8.15

Volume

76,452

Avg. Volume

217,924

Mkt Cap

0

P/E Ratio

-

Dividend Yield

-

Dividend

-

Financials

-130,597.69%Profit Margin

Unprofitable

2020

2021

2022

2023

2024

2025

130,000Revenue

-169.78MNet Income

People Also Follow

This list is based on the watchlists of people on Stock Events who follow DMYD-BTU-B.ST. It's not an investment recommendation.

Xbrane Biopharma AB

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.

Novo Nordisk is a leading global healthcare company that focuses on diabetes care, directly competing with Diamyd Medical's diabetes treatment and vaccine development.

Sanofi is involved in the research, development, and marketing of therapeutic solutions including diabetes management, making it a competitor in the diabetes care market.

Eli Lilly is a major player in the pharmaceutical industry with a strong focus on diabetes care and insulin production, competing in the same space as Diamyd Medical.

Merck & Co., Inc. offers a range of diabetes treatments and management solutions, positioning it as a competitor in the diabetes healthcare sector.

AstraZeneca operates in various therapeutic areas, including diabetes, where it competes with Diamyd Medical through its portfolio of diabetes medications.

Bristol-Myers Squibb

Bristol-Myers Squibb has a presence in the diabetes care market through its development of diabetes treatments, making it a competitor.

Tandem Diabetes Care

Tandem Diabetes Care, Inc. specializes in insulin delivery systems, competing in the diabetes management space with innovative technology solutions.

Insulet Corporation is known for its Omnipod Insulin Management System, competing in the diabetes care market with a focus on insulin delivery technologies.

DexCom, Inc. provides continuous glucose monitoring systems for diabetes management, directly competing in the diabetes care technology market.

MediciNova, Inc. is involved in the development of therapeutic products for diseases with unmet medical needs, including diabetes, positioning it as a competitor in the broader diabetes treatment market.

About

Diamyd Medical AB (publ), a Swedish company founded in Stockholm in 1984, specializes in developing innovative treatments for autoimmune diabetes. Formerly known as Diamyd Therapeutics AB until its name change in April 2013, the company is advancing two key therapeutic candidates. Its flagship product, Diamyd, is an antigen-specific immunotherapy vaccine for diabetes currently undergoing Phase IIb clinical studies for both type 1 diabetes and latent autoimmune diabetes. Additionally, Remygen, an oral drug candidate with regenerative and immunomodulatory properties, is progressing through Phase I/II clinical trials for the treatment of autoimmune and type 2 diabetes.

Show more...

CEO

Employees

44

Country

Sweden

ISIN

SE0020997468

Listings

0 Comments

Share your thoughts

FAQ

What is Diamyd Medical AB stock price today?▼

The current price of DMYD-BTU-B.ST is SEK10.30 SEK — it has increased by +0% in the past 24 hours. Watch Diamyd Medical AB stock price performance more closely on the chart.

What is Diamyd Medical AB stock ticker?▼

Depending on the exchange, the stock ticker may vary. For instance, on Stockholm Exchange exchange Diamyd Medical AB stocks are traded under the ticker DMYD-BTU-B.ST.

What is Diamyd Medical AB revenue for the last year?▼

Diamyd Medical AB revenue for the last year amounts to 130,000 SEK.

What is Diamyd Medical AB net income for the last year?▼

DMYD-BTU-B.ST net income for the last year is -169.78M SEK.

How many employees does Diamyd Medical AB have?▼

As of August 22, 2026, the company has 44 employees.

In which sector is Diamyd Medical AB located?▼

Diamyd Medical AB operates in the Other sector.

When did Diamyd Medical AB complete a stock split?▼

Diamyd Medical AB has not had any recent stock splits.